Navigating an Increasingly Complex Treatment Landscape in the Management of Non-Small Cell Lung Cancer (NSCLC)

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
 Amgen, AstraZeneca, Blueprint Medicines, Lilly, Novartis Pharmaceuticals Corporation,
and Regeneron Pharmaceuticals, Inc and Sanofi Genzyme

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it is expected that there were about 228,150 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 142,670 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include personalized strategies. With the introduction of immunotherapy in recent years, new combination regimens have been discovered that are changing the advanced NSCLC treatment paradigm, especially in first and second-line therapy. These options are improving prognosis and quality of life in NSCLC patients.

As non-small cell lung cancer therapies and treatments continue to both grow and change, it is imperative that we provide healthcare professionals across all spectrums updated information about both NSCLC itself and the treatment options that can greatly improve a patient's quality of life and prognosis. This program will describe the best ways to navigate the ever expanding treatment options in advanced NSCLC, analyzing the use of chemotherapy/immunotherapy combination regimens, providing new updates in the first line management of advanced NSCLC, and recent updates on newer antiangiogenic and TKI combinations in EGFR-mutated advanced NSCLC, ultimately helping patients achieve a greater quality of life and improved clinical outcomes.

Upon completion of this activity, participants will be able to:

  • Analyze recent clinical data on chemotherapy and immunotherapy combination regimens that can be applied to front-line clinical decision making in advanced NSCLC

  • Determine appropriate first-line and subsequent therapy options, including platinum-based chemotherapy and immune checkpoint inhibitors, alone or in combination, for patients with advanced NSCLC without actionable mutations based on clinical trial data and guideline recommendations

  • Evaluate recent evidence on validated treatment options and emerging evidence on the use of novel regimens in the management of EGFR-mutated NSCLC, including newer antiangiogenic and TKI  ombinations or agents

  • Examine evidence-based, individualized, precision treatment plans for patients with advanced EGFR-mutant NSCLC, including for those patients who acquire resistance on prior lines of treatment

  • Assess strategies to proactively plan for and manage treatment-related, adverse events in patients with advanced NSCLC

     

Faculty: Jack West, MD
Associate Clinical Professor
City of Hope Cancer Center Clinical
Executive Director
AccessHope

Disclosure:

Dr. West serves as a consultant for AstraZeneca, Genentech, Merck, Regeneron, and Pfizer. He serves on the speaker's bureau for AstraZeneca and Merck. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
 Amgen, AstraZeneca, Blueprint Medicines, Lilly, Novartis Pharmaceuticals Corporation,
and Regeneron Pharmaceuticals, Inc and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue